Interim management committee of the international drug regulatory agency alliance was established in Beijing

From November 20 to 21, 2014, the Interim Management Committee of the International Federation of drug regulatory agencies was held in Beijing The meeting formally passed the constitution of the Interim Management Committee of the international drug regulatory agency alliance, marking the birth of the international drug regulatory agency alliance Representatives of drug regulatory agencies of 22 countries or international organizations of the Provisional Management Committee of the alliance attended the meeting, and vice director Wu Zhen attended the meeting on behalf of the General Administration of drugs and made concluding remarks On the basis of existing international cooperation actions, the members of the international drug regulatory agency alliance jointly carry out strategic planning, share knowledge, information and experience, and innovate regulatory means; through cooperation, effectively use resources, improve regulatory efficiency, and provide support for capacity-building of drug regulatory agencies in various countries At present, the alliance is in the planning stage, with 13 national drug regulatory agencies including China, Canada, Ireland, the United States, Brazil and the European Union forming the interim management committee, which is responsible for planning and coordinating the relevant work of the alliance in the interim stage In his concluding speech, Wu Zhen congratulated the establishment of the alliance and the adoption of the articles of association, and pointed out that the establishment of the alliance of international drug regulatory agencies is conducive to promoting the cooperation of international regulatory agencies, realizing information sharing, optimizing the allocation of resources and jointly coping with challenges CFDA will continue to support the development of the alliance and actively participate in its work The Interim Management Committee of the alliance not only approved the constitution of the Interim Management Committee of the international drug regulatory agency alliance, but also discussed the work of the Secretariat, project progress and outlook The summary and planning of international cooperation actions, communication with other international organizations and stakeholders, rapid information sharing among alliance members, GMP inspection, generic drug supervision and other temporary work of the alliance were reviewed and inspected Relevant directors and representatives of the General Administration of international cooperation attended the meeting, actively participated in the discussion of relevant topics, and put forward and expressed China's opinions and positions on key contents The 22 members of the alliance are: Ireland, Australia, Brazil, Germany, France, South Korea, the Netherlands, Canada, the United States, Mexico, South Africa, Nigeria, the European Union, Japan, Sweden, Switzerland, Singapore, New Zealand, Italy, the United Kingdom, China, the World Health Organization The 13 core members of the management committee are: Ireland, Australia, Brazil, the Netherlands, Canada, the United States, South Africa, the European Union, Japan, Singapore, Italy, the United Kingdom and China